Clinical Trials

25 Jul 2019
- Clinical Trials
- Human Trials
ViiV Healthcare announces positive week 48 results from TANGO study of dolutegravir/lamivudine

By PBR Staff Writer

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced that data from the phase III TANGO study showed that the 2-drug regimen (2DR) of Dovato (dolutegravir/lamivudine) has similar efficacy to a tenofovir alafenamide fumarate (TAF)-containing regimen of at least three drugs in virally supressed and stable adults with HIV-1.
25 Jul 2019
Clinical Trials
Human Trials
BMS announces mixed results of lung cancer drug Opdivo

By PBR Staff Writer

Bristol-Myers Squibb (BMS) has announced the mixed results from the phase 3 CheckMate -227 trial of the lung cancer drug Opdivo (nivolumab).
23 Jul 2019
Clinical Trials
Human Trials
ViiV’s fostemsavir yields positive week 96 results in phase 3 HIV-1 trial

By PBR Staff Writer

ViiV Healthcare said that a phase 3 trial of fostemsavir in heavily treatment-experienced adults with HIV-1 infection has yielded positive results after 96 weeks of treatment.
23 Jul 2019
Clinical Trials
Human Trials
ACADIA announces top-line results from phase 3 schizophrenia trial of Pimavanserin

By PBR Staff Writer

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced top-line results from its Phase 3 ENHANCE study, which evaluated pimavanserin as an adjunctive treatment in adult schizophrenia patients with persistent inadequate response to their current antipsychotic therapy.
23 Jul 2019
Clinical Trials
Human Trials
Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis

By PBR Staff Writer

Sandoz, a Novartis division and a global leader in biosimilars, announced the first patient enrolled in ROSALIA, an integrated Phase I/III clinical study for its proposed biosimilar denosumab.
19 Jul 2019
Clinical Trials
Human Trials
Transgene receives MHRA approval for clinical trial of next-generation oncolytic virus

By PBR Staff Writer

Transgene has received the approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to proceed with a Phase 1/2a clinical trial of TG6002 administered by intrahepatic artery (IHA) infusion in colorectal cancer patients with unresectable liver metastases (CRLM).
16 Jul 2019
Clinical Trials
Human Trials
GSK’s Zejula meets primary endpoint in phase 3 ovarian cancer trial

By PBR Staff Writer

GlaxoSmithKline (GSK) said that a phase 3 trial evaluating its polymerase (PARP) inhibitor Zejula (niraparib) as a maintenance therapy for first-line ovarian cancer following platinum-based chemotherapy, has met its primary endpoint.
12 Jul 2019
Clinical Trials
Human Trials
SOTIO initiates first-in-human clinical trial with IL-15 superagonist SO-C101

By PBR Staff Writer

SOTIO and Cytune Pharma, members of the PPF Group, announce the first dosing of cancer patients with SO-C101, a superagonist fusion protein of interleukin IL-15.
12 Jul 2019
Clinical Trials
Human Trials
Novartis, Amgen halt Alzheimer’s clinical programme with BACE1 inhibitor

By PBR Staff Writer

Novartis, Amgen and Banner Alzheimer's Institute have decided to halt the clinical programme with BACE1 inhibitor CNP520 (umibecestat) for the prevention of Alzheimer's disease.
11 Jul 2019
Clinical Trials
Human Trials
ViiV Healthcare’s phase 3 study of dolutegravir plus lamivudine meets primary endpoint

By PBR Staff Writer

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 48 results from its phase III TANGO study.

Drug Discovery

Research & Development

Enthorin and Rumi sign agreement for FXS therapy

Astellas and AI Proteins sign miniprotein therapeutics deal

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

Formation Bio launches $600m drug development fund

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Packaging & Supply Chain

Packaging

Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG

Gerresheimer at CPHI Frankfurt 2025

Suppliers

No data found

Clinical Trials

ViiV Healthcare announces positive week 48 results from TANGO study of dolutegravir/lamivudine

BMS announces mixed results of lung cancer drug Opdivo

ViiV’s fostemsavir yields positive week 96 results in phase 3 HIV-1 trial

ACADIA announces top-line results from phase 3 schizophrenia trial of Pimavanserin

Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis

Transgene receives MHRA approval for clinical trial of next-generation oncolytic virus

GSK’s Zejula meets primary endpoint in phase 3 ovarian cancer trial

SOTIO initiates first-in-human clinical trial with IL-15 superagonist SO-C101

Novartis, Amgen halt Alzheimer’s clinical programme with BACE1 inhibitor

ViiV Healthcare’s phase 3 study of dolutegravir plus lamivudine meets primary endpoint

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found